Coronavirus disease 2019 (COVID-19)

Although more than a year has passed since the outbreak of COVID-19, the demand for vaccines is still very high as the global pandemic continues. Due to the continuous outbreaks and prevalence of mutated viruses, additional vaccine doses are required and clinical trials for booster shots are currently underway.As there is a strong bias in the supply of COVID-19 doses, local development is essential in order to stabilize vaccine provision.

Development status

• Established mRNA molecular technology with FTO
• Completed vaccine design using S protein of COVID-19 prototype and virus variant as antigen and started production
• Immunogenicity testing in animals
• Aiming rapid vaccine development and excellent prophylactic efficacy using mRNA technology